Beyond Meat and the American Cancer Society announced a multi-year agreement to advance research on plant-based meat and cancer prevention, as well as to help ACS continue to build the foundation of plant-based meat and diet data collection. The commitment aims to advance the understanding of how plant-based meats contribute to healthy diet patterns and their potential role in cancer prevention and is a crucial step towards long-term research in the plant-based protein field. The agreement will help enable a continuation of ACS’ ongoing data collection in its Cancer Prevention Study-3 and help build a downstream cancer research portfolio that is critical to understanding whether plant-based proteins, including plant-based meat, can play a role in cancer prevention. ACS’ Cancer Prevention Studies help researchers identify cancer risk factors among its pool of more than 300,000 participants.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BYND:
- Beyond Meat price target lowered to $10 from $22 at Bernstein
- Beyond Meat price target lowered to $11 from $27 at Mizuho
- Beyond Meat (NASDAQ:BYND) Misses Q3 Earnings as Revenue Declines Sharply
- Beyond Meat sees Q4 operating expenses mid-$60M range
- Beyond Meat cuts FY22 revenue view to $400M-$425M from $470M-$520M